John L. Berk is an Associate Professor of Medicine at Boston University School of Medicine. He is also the Director of Clinical Trials for Familial Amyloidosis and Localized Amyloid Clinic. He completed his Residency from University Hospitals, Case Western Reserve University School of Medicine (CWRU) and Pulmonary Fellowship from Boston University School of Medicine. Dr. Berk completed his other Post-doctoral Fellowships/ Training from Howard Hughes Medical Institute and is affiliated with Pulmonary, Critical Care and Sleep Medicine.

John Berk attends on the Pulmonary Consult service and in the Medical Intensive Care Units. He directs the Bronchoscopy Service at Boston Medical Center, and is the Pulmonary Medicine and Critical Care expert of the multi-disciplinary Amyloid Treatment and Research Program, an internationally recognized center of excellence.

Dr. Berk is the Principal Investigator for an NIH & FDA funded international trial designed to establish whether diflunisal (Dolobid®) prevents neurologic disease progression in patients with familial amyloidotic polyneuropathy (FAP).

Representative Publications:

Long-term results of conformal radiotherapy for progressive airway amyloidosis

The diflunisal trial: update on study drug tolerance and disease progression

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Share

Discuss in Social Wall

Twitter

Share to rareTeam

myBinder